Key Highlights
- ABBV shares fell 1.81% today to $252.74, down from a prior close of $257.41.
- Q2 adjusted EPS of $3.65 topped the $3.60 consensus, with revenue of $16.99 billion beating estimates, driven by continued strength in Skyrizi and Rinvoq.
- AbbVie cut its 2026 EPS outlook to $13.87-$14.07, below the $14.06-$14.08 Street estimate, to reflect dilution from its pending $10.9 billion acquisition of Apogee Therapeutics.
- JPMorgan raised its price target to $285 on the stock despite the guidance cut.
Guidance Cut Overshadows Immunology Strength
AbbVie Inc. (NYSE:ABBV) shares are declining today after the company reported strong second-quarter 2026 results but trimmed its full-year adjusted EPS guidance, overshadowing the headline earnings beat. AbbVie, headquartered in North Chicago, Illinois and formed in 2013 as a spin-off from Abbott Laboratories, is a global research-driven biopharmaceutical company that discovers, develops, manufactures and commercializes advanced therapies across immunology, oncology, neuroscience, virology, eye care and aesthetics.
Q2 adjusted EPS of $3.65 topped the $3.60 consensus, and revenue of $16.99 billion beat estimates, driven by continued strength in Skyrizi and Rinvoq, both of which the company noted have driven double-digit growth in its immunology portfolio. Despite this, AbbVie cut its 2026 EPS outlook to $13.87-$14.07, below the $14.06-$14.08 Street estimate, to reflect $0.14 of dilution from its pending $10.9 billion acquisition of Apogee Therapeutics, expected to close in the third quarter.
Pipeline Progress and Balance Sheet Priorities
AbbVie carries a market capitalization of approximately $446.54 billion, with shares trading at a trailing price-to-earnings ratio of 24.80 and a dividend yield of 2.71%. The stock's 52-week range spans $189.79 to $267.47.
Investors are weighing the guidance cut against otherwise robust immunology and neuroscience growth, with the stock underperforming the broader healthcare sector and S&P 500, which both traded higher today, even as JPMorgan raised its price target to $285 following the print. Key pipeline highlights include Skyrizi's subcutaneous induction formulation for Crohn's disease under FDA review, with a decision expected in the fall of 2026, and Rinvoq's approval in Europe for vitiligo and alopecia areata, with U.S. decisions anticipated that could push combined peak sales toward $2 billion.
For the third quarter, AbbVie guided net revenues of approximately $17.2 billion and adjusted EPS between $3.84 and $3.88, which includes a partial quarter of Apogee dilution but excludes acquired in-process research and development expense. The company maintains a commitment to reach a net leverage ratio of 2x within two to three years following the Apogee transaction's close, while continuing to pursue additional business development opportunities across its core disease areas.
Conclusion
AbbVie's decline despite a genuine earnings beat reflects investor focus on the near-term dilutive impact of its Apogee Therapeutics acquisition rather than any weakness in the underlying immunology and neuroscience franchises. With Skyrizi and Rinvoq continuing to drive double-digit growth and several pipeline catalysts on the horizon, investors will be watching whether the strategic case for the Apogee deal offsets the near-term guidance headwind.
This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.






Please wait processing your request...